AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27966269 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral intraocular lenses (IOL)
Number of subjects: 67
Study 27966269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with blue-blocking IOLs
Number of subjects: 67
Study 27966269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with neutral IOLs
Number of subjects: 67
Study 27966269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 67
Study 25740882 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐FSH/r‐LH (Pergoveris(®)) 150/75 IU/day
Number of subjects: 240
Study 25740882 — intervention group
Group type: COMPARATOR
Intervention: r‐FSH
Number of subjects: 240
Study 23847256 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1480 (10-70 mg QD and 20-45 mg b.i.d.)
Number of subjects: 38
Study 21030612 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 2 g
Number of subjects: 13
Study 21030612 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 13
Study 19426177 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment before 21 weeks of gestation
Number of subjects: 812
Study 19426177 — intervention group
Group type: COMPARATOR
Intervention: Periodontal treatment after delivery
Number of subjects: 812
Study 19426177 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-progressing group (no disease progression)
Number of subjects: 812
Study 19426177 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressing group (disease progression defined as >or=3 mm loss of clinical attachment)
Number of subjects: 812
Study 16960174 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg/d as zinc sulfate)
Number of subjects: 85
Study 16960174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 15248795 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received inservice training on facilitating peer interaction using verbal support strategies.
Number of subjects: 17
Study 15248795 — intervention group
Group type: COMPARATOR
Intervention: Control group received training on adult‐child communication strategies.
Number of subjects: 17
Study 15248795 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (children) initiated interactions with peers more often and engaged in extended peer sequences more often than the control group (children).
Number of subjects: 17
Study 11096377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 2.5%
Number of subjects: 18
Study 11096377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11096377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1%
Number of subjects: 18
Study 11096377 — intervention group
Group type: COMPARATOR
Intervention: Placebo, Hydrocortisone 1%, Hydrocortisone 2.5%
Number of subjects: 18
Study 9075561 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rectally of diclofenac (n = 31)
Number of subjects: 62
Study 9075561 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 62
Study 8471832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg
Number of subjects: 12
Study 8471832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 12
Study 8471832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3816879 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg intravenous infusion
Number of subjects: 6
Study 3816879 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral solution
Number of subjects: 6
Study 3816879 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tablet administration
Number of subjects: 6
Study 31931770 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulated learning training
Number of subjects: 600
Study 31931770 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 600
Study 29633099 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 63
Study 29633099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 63
Study 29633099 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 63
Study 28381155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy intervention (9-month outpatient intervention)
Number of subjects: 751
Study 28381155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 751
Study 26818900 — intervention group
Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 199
Study 26818900 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education (scenario 1)
Number of subjects: 199
Study 26818900 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education (scenario 2)
Number of subjects: 199
Study 26818900 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education (scenario 3)
Number of subjects: 199
Study 23173717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 48
Study 21927052 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine (30 mg, 3 mL) plus triamcinolone (80 mg, 2 mL) and bupivacaine (0.25%, 3 mL)
Number of subjects: 200
Study 21927052 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid injection (80 mg triamcinolone, 2 mL) and 0.25% bupivacaine (3 mL) plus saline (3 mL)
Number of subjects: 200
Study 21927052 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine
Number of subjects: 200
Study 21927052 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid injection with saline
Number of subjects: 200
Study 18564342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg/day
Number of subjects: 1624
Study 18564342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1624
Study 16612469 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (CG)
Number of subjects: 16
Study 16612469 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 16
Study 14564361 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw maize hybrids
Number of subjects: 22
Study 14564361 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-treated maize hybrids
Number of subjects: 22
Study 14564361 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize LTP
Number of subjects: 22
Study 11018575 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8898645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin plus interferon alfa 2a (1200 mg oral ribavirin daily plus 3 million units of recombinant interferon alfa 2a thrice weekly for 24 weeks)
Number of subjects: 60
Study 8898645 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa 2a alone (3 million units thrice weekly for 24 weeks)
Number of subjects: 60
Study 8898645 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 60
Study 1797521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 0.5 mg
Number of subjects: 0
Study 1797521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 1.0 mg
Number of subjects: 0
Study 1797521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 2.0 mg
Number of subjects: 0
Study 1797521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 0
Study 6813902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum smoking of a standard cigarette
Number of subjects: 12
Study 6813902 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking a standard cigarette with a prescribed puff pattern
Number of subjects: 12
Study 6813902 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum smoking of their own cigarette
Number of subjects: 12
Study 31987519 — intervention group
Group type: EXPERIMENTAL
Intervention: Back/front backpack design
Number of subjects: 12
Study 31987519 — intervention group
Group type: COMPARATOR
Intervention: Back only backpack design
Number of subjects: 12
Study 30747773 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936559 (10-900 mg)
Number of subjects: 24
Study 30747773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30747773 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936559 (900 mg)
Number of subjects: 24
Study 30747773 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936559 (at two highest doses)
Number of subjects: 24
Study 28160375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7913
Study 28160375 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 7913
Study 25500489 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsh model
Number of subjects: 60
Study 25500489 — intervention group
Group type: COMPARATOR
Intervention: Schnider model
Number of subjects: 60
Study 25500489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 60
Study 23152491 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in pulmonary capillary wedge pressure (PCWP)
Number of subjects: 233
Study 23152491 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in mean pulmonary artery pressure
Number of subjects: 233
Study 21756381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil rehabilitation (Group 2)
Number of subjects: 65
Study 21756381 — intervention group
Group type: COMPARATOR
Intervention: Control without rehabilitation (Group 1)
Number of subjects: 65
Study 19500154 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200 mg once-daily with digoxin
Number of subjects: 12
Study 19500154 — intervention group
Group type: COMPARATOR
Intervention: Placebo with digoxin
Number of subjects: 12
Study 16337719 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN (IMVAMUNE) vaccine, highest dose (10^8 TCID50)
Number of subjects: 86
Study 16337719 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN (IMVAMUNE) vaccine
Number of subjects: 86
Study 15344392 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg once a day
Number of subjects: 57
Study 15344392 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice a day
Number of subjects: 57
Study 10653828 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR
Number of subjects: 426
Study 8369980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cetirizine
Number of subjects: 10
Study 8369980 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cetirizine
Number of subjects: 10
Study 8369980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3723261 — intervention group
Group type: EXPERIMENTAL
Intervention: 2:1 regimen (60 ml WHO‐ORS followed by 30 ml plain water)
Number of subjects: 50
Study 3723261 — intervention group
Group type: COMPARATOR
Intervention: Diluted WHO‐ORS (1.5 L water instead of 1 L)
Number of subjects: 50
Study 31702432 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated methotrexate, vinblastine, doxorubicin and cisplatin
Number of subjects: 30
Study 31702432 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin
Number of subjects: 30
Study 30326762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Task Analysis (CTA) tool
Number of subjects: 22
Study 30326762 — intervention group
Group type: COMPARATOR
Intervention: Standard operative technique manual
Number of subjects: 22
Study 27181606 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (110 μg) plus Glycopyrronium (50 μg) once daily
Number of subjects: 3362
Study 27181606 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 μg) plus Fluticasone (500 μg) twice daily
Number of subjects: 3362
Study 24084500 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg intravitreal ranibizumab every 4 weeks (Rq4)
Number of subjects: 2457
Study 24084500 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept every 4 weeks (2q4)
Number of subjects: 2457
Study 24084500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg aflibercept every 4 weeks (0.5q4)
Number of subjects: 2457
Study 24084500 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept every 8 weeks (2q8)
Number of subjects: 2457
Study 24084500 — intervention group
Group type: EXPERIMENTAL
Intervention: All aflibercept and ranibizumab groups
Number of subjects: 2457
Study 24084500 — intervention group
Group type: EXPERIMENTAL
Intervention: 2q8 aflibercept group
Number of subjects: 2457
Study 24084500 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2457
Study 22112804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (800 IU)
Number of subjects: 5292
Study 22112804 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg)
Number of subjects: 5292
Study 20738227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg with atorvastatin (concurrent dosing study)
Number of subjects: 78
Study 20738227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg with atorvastatin (interval dosing study)
Number of subjects: 78
Study 18219298 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG strain and albuminuria present
Number of subjects: 7786
Study 18219298 — intervention group
Group type: EXPERIMENTAL
Intervention: Only ECG strain present
Number of subjects: 7786
Study 18219298 — intervention group
Group type: EXPERIMENTAL
Intervention: Only albuminuria present
Number of subjects: 7786
Study 18219298 — intervention group
Group type: COMPARATOR
Intervention: Neither strain nor albuminuria present
Number of subjects: 7786
Study 18219298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strain and albuminuria present
Number of subjects: 7786
Study 18219298 — intervention group
Group type: EXPERIMENTAL
Intervention: Only strain present
Number of subjects: 7786
Study 15689804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids (for 1 week)
Number of subjects: 20
Study 15689804 — intervention group
Group type: COMPARATOR
Intervention: No oral steroids
Number of subjects: 20
Study 15689804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after reoperation)
Number of subjects: 20
Study 12908569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 40
Study 12908569 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 40
Study 10588563 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous psoas compartment block (CPCB)
Number of subjects: 40
Study 10588563 — intervention group
Group type: COMPARATOR
Intervention: Traditional pain management with meperidine
Number of subjects: 40
Study 8823700 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational/cognitive intervention (ECO)
Number of subjects: 131
Study 8823700 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational discussion intervention (EDI)
Number of subjects: 131
Study 8823700 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 131
Study 1395875 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative chemotherapy (5-FU 1g/m2/d x 5 and cisplatin 20 mg/m2/d x 5)
Number of subjects: 46
Study 1395875 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative chemotherapy
Number of subjects: 46
Study 1395875 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 46
Study 3902911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24
Study 3902911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29228369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 10
Study 29228369 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 10
Study 28940820 — intervention group
Group type: EXPERIMENTAL
Intervention: ET with NIV
Number of subjects: 42
Study 28940820 — intervention group
Group type: COMPARATOR
Intervention: ET alone
Number of subjects: 42
Study 29653037 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Titration (MT) technique
Number of subjects: 90
Study 29653037 — intervention group
Group type: COMPARATOR
Intervention: Target-Controlled Infusion (TCI)
Number of subjects: 90
Study 23135529 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus naltrexone (0.7 mg/kg)
Number of subjects: 42
Study 23135529 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 42
Study 23135529 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus naltrexone (0.7 mg/kg)
Number of subjects: 42
Study 23135529 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 42
Study 22115988 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic ignoring with minimal check ('SI‐mc')
Number of subjects: 16
Study 22115988 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence with minimal check ('PP‐mc')
Number of subjects: 16
Study 20470677 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal hemostatic matrix
Number of subjects: 0
Study 20470677 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 0
Study 18474932 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (3 doses, twice daily for 2 weeks)
Number of subjects: 31
Study 18474932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16040376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (0.05-0.2 mg per day)
Number of subjects: 42
Study 16040376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one to four tablets per day)
Number of subjects: 42
Study 12444336 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight-independent (BWI) dosing of cyclosporine A (CsA) 100-300 mg for 12 weeks
Number of subjects: 122
Study 12444336 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight-dependent (BWD) dosing of cyclosporine A (CsA) 1.25-5.0 mg/kg for 12 weeks
Number of subjects: 122
Study 12444336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent CsA treatment (after period I)
Number of subjects: 122
Study 12444336 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (after period I)
Number of subjects: 122
Study 10606177 — intervention group
Group type: EXPERIMENTAL
Intervention: Brahma Rasayana (BR)
Number of subjects: 0
Study 10606177 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control)
Number of subjects: 0
Study 8602320 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-based intervention with self-help materials and goal-setting scripts
Number of subjects: 250
Study 8602320 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (control)
Number of subjects: 250
Study 8602320 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-based intervention
Number of subjects: 250
Study 1294411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 157
Study 1294411 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 157
Study 6207983 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40-320 mg/day)
Number of subjects: 204
Study 6207983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propranolol)
Number of subjects: 204
Study 30710418 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular professional brushing by a dental nurse every 2 weeks for 3 months (n = 25)
Number of subjects: 50
Study 30710418 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene procedures performed/controlled by nursing home staff (n = 25)
Number of subjects: 50
Study 28636435 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast training programme (isometric + plyometric), twice a week for 10 weeks
Number of subjects: 58
Study 28636435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study 27213949 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/day) + Naltrexone (50 mg/day)
Number of subjects: 121
Study 27213949 — intervention group
Group type: COMPARATOR
Intervention: Bupropion (300 mg/day) + Placebo
Number of subjects: 121
Study 24489770 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole - ATM)
Number of subjects: 20
Study 24489770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24489770 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (ATM)
Number of subjects: 20
Study 22992449 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program (six-week intervention with four individual and two group counselling sessions)
Number of subjects: 48
Study 22992449 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program (six-week intervention)
Number of subjects: 48
Study 22992449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 21051252 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (1.6 mU/kg/h) for 4 hours before hemodialysis
Number of subjects: 5
Study 17350775 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaussian noise at levels from audible to inaudible (0.0 to -35.0 dB/Hz)
Number of subjects: 0
Study 17350775 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform noise at levels from audible to inaudible (0.0 to -35.0 dB/Hz)
Number of subjects: 0
Study 17350775 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low noise levels (-30.0 to -35.0 dB/Hz)
Number of subjects: 0
Study 17350775 — intervention group
Group type: COMPARATOR
Intervention: Quiet (no noise)
Number of subjects: 0
Study 15563637 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbitrary‐pressure CPAP based on body mass index before treatment polysomnography
Number of subjects: 91
Study 15563637 — intervention group
Group type: COMPARATOR
Intervention: CPAP at settings determined by polysomnography
Number of subjects: 91
Study 15563637 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbitrary‐pressure CPAP
Number of subjects: 91
Study 12125474 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcimax (200 mg per capsule, 2 capsules after light supper for 6 months)
Number of subjects: 31
Study 12125474 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31